Is coronary multivessel disease in acute myocardial infarction patients still associated with worse clinical outcomes at 1‐year?. Issue 3 (14th February 2021)

• Record Type: Journal Article
• Authors: Puymirat, Etienne; Nakache, Ariel; Saint Etienne, Christophe; Marcollet, Pierre; Fichaux, Olivier; Decomis, Marie‐Pascale; Chassaing, Stephan; Commeau, Philippe; Danchin, Nicolas; Cayla, Guillaume; Montalescot, Gilles; Benamer, Hakim; Koning, Rene; Motreff, Pascal; Rangé, Grégoire
• Is Part Of: Clinical cardiology. Volume 44:Issue 3(2021)
• Page Start: 429
• Page End: 437
• Publication Date: 2021-02-14
• Subjects: acute myocardial infarction -- multivessel disease -- primary percutaneous coronary intervention -- ST‐elevation myocardial infarction; Cardiology -- Periodicals; 616.12005
• DOI: 10.1002/clc.23567
• Languages: English
• ISSNs: 0160-9289

Abstract

Abstract: Background: ST‐elevation myocardial infarction (STEMI) patients with multivessel disease (MVD) are associated with a worse prognosis. However, few comparisons are available according to coronary status in the era of modern reperfusion and optimized secondary prevention. Hypothesis: We hypothesized that the difference in prognosis according to number of vessel disease in STEMI patients has reduced. Methods: All consecutive STEMI patients undergoing primary percutaneous coronary intervention (PCI) within 24 h of symptoms onset between January 1, 2014 and June 30, 2016 enrolled in the CRAC (Club Régional des Angioplasticiens de la région Centre) France PCI registry were analyzed. Baseline characteristics, management, and outcomes at 1‐year were analyzed according to coronary status (one‐, two‐, and three‐VD). Results: A total of 1886 patients (mean age 62.2 ± 14.0 year; 74% of male) were included. Patients with MVD (two or three‐VD) represented 53.7%. They were older with higher cardiovascular risk factor profile. At 1 year, the rate of major adverse cardiovascular events (MACE, defined as all‐cause death, stroke or re‐MI) was 10%, 12%, and 12% in one‐, two, and three‐VD respectively ( p = .28). In multivariable adjusted Cox proportional hazard regression model, two‐ and three‐VD were not associated with higher rate of MACE compared to patients with single VD (HR, 1.09; 95%CI 0.76–1.56 for two‐VD; HR, 0.74; 95%CI 0.48–1.14 for three‐VD). Conclusions: MVD still represents an important proportion of STEMI patients but their prognoses were not associated with worse clinical outcomes at 1‐year compared with one‐VD patients in a modern reperfusion area and secondary medication prevention.